Available COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays.

  1. Francisco Belda
  2. Monica Lopez-Martinez
  3. Nerea Torres
  4. Robin Cherenzia
  5. Michael Crowley

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.diagmicrobio.2021.115340
  2. ScreenIT

    SciScore for 10.1101/2020.09.08.20190256: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementConsent: The samples were collected with informed consent, under an approved IRB protocol (Advarra, Columbia MD, USA) and in compliance with all applicable regulatory guidelines.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Five anti-SARS-CoV-2 antibody tests were used in this study to characterize a COVID-19 seroconversion panel (COVID-19 Seroconversion Panel: CVD19SCP, Access Biologicals, Vista, CA, USA).
    anti-SARS-CoV-2
    suggested: None
    The antibody tests used were: the Gold Standard™ Diagnostics SARS-CoV-2 IgG ELISA and SARS-CoV-2 IgM ELISA test kits (Gold Standard™ Diagnostics (GSD), Davis, CA, USA; CE-IVD certified immunoassays, emergency use authorization (EUA) submission pending), Vitros® anti-SARS-CoV-2 IgG and anti-SARS-CoV-2 total Ig tests (Vitros® Immunodiagnostic Products, Ortho-Clinical Diagnostics, Inc., Rochester, NY, USA; EUA approved) and Liaison® SARS-CoV-2 S1/S2 IgG assay (Diasorin, Inc., Saluggia, Italy; EUA approved).
    SARS-CoV-2 IgM
    suggested: None
    anti-SARS-CoV-2 IgG
    suggested: None
    Plasma from this single donor was screened and found to be negative for syphilis and antibodies to HIV-1/2 HCV and non-reactive for hepatitis B surface antigen (HBsAg).
    HIV-1/2
    suggested: None
    HCV
    suggested: None
    antigen (HBsAg).
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.09.08.20190256v2 on medRxiv
  4. Version published to 10.1101/2020.09.08.20190256v1 on medRxiv